April 26th 2024
Encouraging responses were observed in most patients with relapsed/refractory follicular lymphoma treated with loncastuximab tesirine and rituximab.
The Latest on Acute Lymphocytic Leukemia
View More
A Focus on Acute Myeloid Leukemia
View More
Updates in Myelodysplastic Syndromes
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Go To PER in Chicago
May 31, 2024 - June 2, 2024
Register Now!
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
7th Annual Live Medical Crossfire®: Hematologic Malignancies
View More
Community Practice Connections™: Integrating BTK Inhibitors Into the CLL/SLL and MCL Treatment Paradigm
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies, Combinations, and Clinical Trials Across MPN Care in the Context of Current Treatment Algorithms?
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
G-CSF Underused in Older Patients Receiving Immunochemotherapy for DLBCL
November 15th 2016Older patients with diffuse large B-cell lymphoma (DLBCL) often have an increased risk of treatment-related morbidity and mortality, but the use of preventive interventions, such as granulocyte colony-stimulating factor (G-CSF) may help.
Blinatumomab Approved for Pediatric Acute Lymphoblastic Leukemia
September 2nd 2016Blinatumomab (Blincyto) gained accelerated approval by the FDA for the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)
Ofatumumab Triplet Approval Expands Treatment Options for Relapsed CLL
August 31st 2016Following on a 10-month improvement in progression-free survival (PFS), the FDA has approved ofatumumab (Arzerra) in combination with fludarabine and cyclophosphamide as a treatment for patients with with relapsed chronic lymphocytic leukemia (CLL).
Talking With PA Maureen E. Thyne About Ruxolitinib for Myelofibrosis
May 27th 2016Though there are few therapeutic options for patients with myelofibrosis, ruxolitinib (Jakafi) represents an important look towards the future, according to Maureen E. Thyne, a physician assistant in the Outpatient Leukemia Service at Weill Cornell Medical College.
FDA Approves Nivolumab for Hodgkin Lymphoma
May 17th 2016The FDA granted nivolumab (Opdivo) accelerated approval for the treatment of patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and posttransplantation brentuximab vedotin (Adcetris).
Intervention Eases Parental Caregiver Burden During Child's HSCT
April 27th 2016An intervention specifically aimed at reducing the trauma and anxiety that often comes with parenting a child undergoing hematopoietic stem cell transplant proved especially helpful for parents during the time of the actual transplant and subsequent hospitalization.
FDA Expands Ibrutinib for Use in Previously Untreated Patients With CLL
March 9th 2016An impressive improvement in progression-free survival (PFS) in the RESONATE-2 trial led to the FDA’s approval of ibrutinib (Imbruvica) March 4 for the frontline treatment of chronic lymphocytic leukemia, based on data from the RESONATE-2 trial.
Phyllis McKiernan on Blood and Marrow Transplants and Targeted Therapies
January 19th 2016Phyllis McKiernan, MSN, APN, OCN, nurse practitioner, John Theurer Cancer Center at Hackensack University Medical Center, discusses blood and marrow transplantation and treating chronic myeloid leukemia (CML) with targeted therapies.
Sagar Lonial Discusses Treating Patients With Myeloma
December 23rd 2015Sagar Lonial, MD, chief medical officer, Winship Cancer Institute of Emory University and Professor and Executive Vice Chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, discusses treating patients with myeloma.